Stockscreener 앱 받기
31.11
4.78%
-1.56
시장 영업 전:
31.24
0.13
+0.42%
전일 마감가:
$32.67
열려 있는:
$32.48
하루 거래량:
864.67K
Relative Volume:
0.48
시가총액:
$6.39B
수익:
-
순이익/손실:
$-464.20M
주가수익비율:
-11.60
EPS:
-2.6823
순현금흐름:
$-423.09M
1주 성능:
-6.58%
1개월 성능:
+11.75%
6개월 성능:
+36.21%
1년 성능:
+94.19%
1일 변동 폭
$30.78
$32.88
1주일 범위
$30.33
$33.32
52주 변동 폭
$14.32
$36.28
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
31.11 | 6.71B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant Inc stock (US45258Q1058): shares trade around mid-30 USD ahead of next catalysts - AD HOC NEWS
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary - Yahoo Finance
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
IMVT Technical Analysis & Stock Price Forecast - Intellectia AI
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data - Insider Monkey
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options - Stock Titan
Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum - simplywall.st
[144] Immunovant, Inc. SEC Filing - Stock Titan
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating - Insider Monkey
J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Selling US$2.3m Of Stock Was Lucrative Decision For Immunovant Insiders - 富途牛牛
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers - Barron's
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT) - Seeking Alpha
(IMVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune PivotHas The Bull Case Changed? - simplywall.st
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Immunovant COO Gloria Melanie sells $101,072 in company stock By Investing.com - Investing.com Australia
Immunovant COO Gloria Melanie sells $101,072 in company stock - Investing.com
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT) - The Globe and Mail
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Sahm
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $43 - Moomoo
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications - TipRanks
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider LossesHas The Bull Case Changed? - Yahoo Finance
Immunovant director Atul Pande sells $192,000 in shares By Investing.com - Investing.com Nigeria
IMVT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IMVT Maintains Buy Rating by B of A Securities -- Price Target R - GuruFocus
IMVT Maintains by HC Wainwright & Co. -- Price Target Raised to $40 - GuruFocus
Immunovant (IMVT) Stock Shot up after a Poor Quarterly Showing - FXLeaders
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $45 - Moomoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - The Globe and Mail
BofA raises Immunovant stock price target on higher peak sales outlook - Investing.com
Stifel reiterates Immunovant stock rating on trial results By Investing.com - Investing.com Australia
Immunovant director Atul Pande sells $192,000 in shares - Investing.com India
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fromkin Andrew J. | Director |
May 28 '26 |
Sale |
33.51 |
221,951 |
7,438,111 |
74,382 |
1.13%
3.22%
자본화:
|
볼륨(24시간):